Truist analyst Joon Lee raised the firm’s price target on AnaptysBio (ANAB) to $36 from $20 and keeps a Hold rating on the shares. The company’s Q3 benefitted from $50M in Jemperli milestones and growing royalties, with another $75M in milestones expected in Q4, the analyst tells investors in a research note. Near-term catalysts for the stock include Phase 2 UC update in November-December and Vanda’s (VNDA) imsidolimab BLA submission in Q4 for GPP, which is tied to milestones for AnaptysBio, the firm added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio: Phase 2 rosnilimab trial did not meet primary, secondary endpoints
- AnaptysBio trading halted, news pending
- AnaptysBio’s Strategic Split and Robust Pipeline Justify Buy Rating
- AnaptysBio Reports Q3 2025 Results and Strategic Plans
- AnaptysBio’s Strategic Split and Promising Clinical Developments Drive Buy Rating